Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI
Condition(s) studied
Investigational drug(s) / intervention(s)
Memantine Oral Tablet: Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy
Study summary
The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.
Eligibility
Primary outcome measure(s)
- Cognitive-deterioration-free survival at 2 years — 2 years
Cognitive-deterioration-free survival at 2 years; defined by a drop of 5 points in any of Full Scale Intelligence Quotient (FSIQ), Verbal Intelligence Quotient (VIQ), or Performance Intelligence Quotient (PIQ) compared to baseline (pre-radiation) on Wechsler Adult Intelligence Scale (WAIS), and Wechsler Intelligence Scale for Children (WISC).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Tata Memorial Hospital | Mumbai | Maharashtra | Recruiting |
More Tata Memorial Centre trials in India
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06275035 on ClinicalTrials.gov ↗ ← All trials in India